Tag: KDC-MN-357

  • Loratadine

    Second-generation H1 antihistamine (peripheral)

    A piperidine second-generation H1 antihistamine; a non-sedating allergy medication and the prodrug of desloratadine.

    Abstract

    Loratadine (ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate; CAS 79794-75-5; molecular formula C22H23ClN2O2; molecular weight 382.88) is a piperidine second-generation H1 antihistamine developed at Schering-Plough and approved by the FDA in 1993 (Claritin). H1 affinity is approximately 100 nM, lower than cetirizine but with similar peripheral selectivity (minimal CNS penetration). The principal active species is the metabolite desloratadine (formed via CYP3A4 and CYP2D6), which has higher H1 affinity (approximately 0.4 nM) and longer half-life; desloratadine is marketed separately as Clarinex. Plasma half-life of loratadine is approximately 8 hours; desloratadine half-life is approximately 27 hours. Approved indications: allergic rhinitis, urticaria. Sedation incidence is approximately 8 percent (similar to placebo in most trials), the lowest of the second-generation antihistamines. Used as the canonical non-sedating H1 antihistamine in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.